


15m 1626



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
**1662/50302**

Application Number  
**09/714,351**

Filing Date  
**November 16, 2000**

Examiner  
**Laura Stockton**

Art Unit  
**1626**

Invention Title  
**POLYMORPHIC FORM OF ATORVASTATIN CALCIUM**

Inventor(s)  
**AYALON et al.**

Address to:  
Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: May 11, 2005  
Signature: Kathy Felf

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. § 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached references to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Copies of patents, publications or other information listed on the modified PTO Form 1449 are enclosed, unless indicated otherwise.
3. A copy of a Supplemental European Search Report recently received in a corresponding EP application is also enclosed.
4. Applicants' attorney certifies that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
5. A duplicate copy of this communication is enclosed for charging purposes.

Dated: MAY 10, 2005

By: Joseph A. Coppola  
Joseph A. Coppola (Reg. No. 38,413)

**CUSTOMER NUMBER 26646**

**KENYON & KENYON**  
One Broadway  
New York, New York 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)



<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT PTO-1449</b>	<b>ATTY. DOCKET NO.</b> 1662/50302	<b>SERIAL NO.</b> 09/714,351
	<b>APPLICANT</b> AYALON et al.	
	<b>FILING DATE</b> November 16, 2000	<b>GROUP</b> 1626

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/03958	February 6, 1997	PCT			x	
	WO 97/03959	February 6, 1997	PCT			x	
	WO 01/36384	May 25, 2001	PCT			x	
	WO 01/44180	June 21, 2001	PCT			x	
	WO 01/44181	June 21, 2001	PCT			x	
	WO 02/41834	May 30, 2002	PCT			x	
	WO 02/43732	June 6, 2002	PCT			x	
	WO 02/051804	July 4, 2002	PCT			x	
	WO 02/057229	July 25, 2002	PCT			x	
	WO 03/004470	January 16, 2003	PCT			x	
	WO 03/011826	February 13, 2003	PCT			x	
	WO 03/050085	June 19, 2003	PCT			x	
	WO 2004/022053	March 18, 2004	PCT			x	
	WO 2004/050618	June 17, 2004	PCT			x	

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

**PARTNERS**  
ADAM PILCH \*  
PENELOPE NICHOLLS †  
NIGEL ROBINSON \*  
IAN HARRIS \*  
CHARLES HARDING \*  
JEREMY PENNANT †  
JAMES TURNER \*  
CATHERINE MALLALIEU \*  
RICHARD PRATT \*  
ANTONIO MASCHIO \*  
DAVID HORNER \*  
NEIL NACHSHEN \*  
MILES HAINES \*  
JONATHAN DEVILE \*  
DAVID ALCOCK \*  
CHONG YEE KHOO \*  
LOUISE HOLLIDAY \*  
SIMON DAVIES \*  
GILLIAN DEAS †  
KIRK GALLAGHER \*  
ZOE CLYDE - WATSON \*  
AYLSA WILLIAMS \*

**ASSOCIATES**  
PAUL PRICE \*  
JILL MATCHETT †  
JAMES TANNER \*  
JULIA MILLS \*  
ANGELA THORNTON - JACKSON †  
CATHERINE MCGOWAN \*  
ISLA FURLONG \*  
WILLIAM ILLINGWORTH - LAW \*  
JOSEPHINE BRADLEY \*  
KARA BEARFIELD †  
DAVID MELDRUM \*  
GARETH FENNELL \*  
CANDIDA SOAMES \*  
ANDREW LEPPARD \*  
KIT WONG \*  
ADRIAN BRADLEY \*

**CONSULTANTS**  
IVAN COTTER \*  
DAVID CRISP \*  
JOHN ARDLEY, OBE §  
JANE HARLOW †

**ADMINISTRATION**  
KEITH TESTER (DIRECTOR OF OPERATIONS)  
DAVID SHARPE (PATENT AND DESIGN RECORDS  
AND RENEWALS)  
SHARON SEQUEIRA (TRADE MARK RECORDS  
AND RENEWALS)


\* CHARTERED PATENT ATTORNEY AND EUROPEAN  
PATENT ATTORNEY  
† EUROPEAN TRADE MARK ATTORNEY  
§ CONSULTANT IN PLANT BREEDERS' RIGHTS ONLY  
‡ PATENT AGENT LITIGATOR

**D. YOUNG & CO**

CHARTERED PATENT ATTORNEYS  
EUROPEAN PATENT ATTORNEYS  
EUROPEAN TRADE MARK ATTORNEYS  
EUROPEAN DESIGN ATTORNEYS

120 HOLBORN  
LONDON  
EC1N 2DY

TELEPHONE: +44 (0) 20 7269 8550  
FAX: +44 (0) 20 7269 8555  
E MAIL: mail@dyoung.co.uk  
WEBSITE: www.dyoung.com  
DX.0078 LONDON, CHANCERY LANE  
ALSO AT MUNICH



**COPY**

*KATHY FALL*  
Ms Galit Gonen-Cohen,  
Teva Pharmaceutical Industries Ltd.,  
Patents Department,  
5 Basel Street,  
P.O. Box 3190,  
Petah Tiqva 49131,  
Israel.

Our Ref: P020440EP JNB CHM  
Your Ref: 3977-A-PCT-EP

CC: Patrick J. Birde, Kenyon & Kenyon (Ref: 1662/503364)  
Lori Azuolay, Teva Pharmaceutical Industries Ltd.

27 April 2005

Dear Galit,

**European Patent Application No. 03713610.8  
Regional Phase of PCT/US03/05384**

**"Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as  
novel processes for preparing atorvastatin hemi-calcium forms I, VIII and IX"  
Teva Pharmaceutical Industries Ltd.**

I enclose a copy of an Official Letter from the EPO dated 6 April 2005 which includes a copy of the EPO Supplementary Search Report, a copy of a list of equivalents provided by the EPO and copies of the cited references. As you will see, the Search Examiner considers eleven of the cited references to be particularly relevant if taken alone but the Substantive Examiner in Munich may take a different view.

There is no need to comment on the references or file amendments at this stage but if we do so, this may expedite prosecution.

We will shortly receive an Official Letter setting a term of two months within which time we must confirm to the European Patent Office that the application is to proceed to full examination.

**DOCKET DEPARTMENT**

DOCKETED BY \_\_\_\_\_

CHECKED BY ALB 5/5/05

27 April 2005

- 2 -



I will contact you again when I receive the expected Official Letter. In the meantime, I enclose our debit note.

Yours sincerely,  
for D Young & Co

Jo Bradley